Overview
SNTI market data
Price History
SNTI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.73 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.16 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.35 – $2.88 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $10.8 · P/B 4.89 · P/S 284.40.
Company News
Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jul 15, 2026, 11:55 AM
Senti Biosciences Signs Agreement To Sell Assets Related To Its Gene-Circuit-Enabled Pipeline To Celadon For Up To $60M In Milestone Payments Over Seven YearsBenzinga · Jul 15, 2026, 11:33 AM
8-K filing — Senti Biosciences Holdings, Inc. (SNTI)SEC EDGAR · Jul 15, 2026, 11:32 AM
Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News PendingBenzinga · Jul 15, 2026, 11:25 AM
Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12Benzinga · May 15, 2026, 12:25 PM
Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000KBenzinga · May 14, 2026, 12:46 PM
Senti Biosciences Announces Completion Of Type B Initial Comprehensive Multidisciplinary RMAT Meeting With FDA Regarding SENTI-202, Logic Gated Off-The-Shelf CAR-NK Cell Therapy For R/R AML And Updated Phase 1 Clinical DataBenzinga · May 14, 2026, 12:43 PM